BlackRock’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

BlackRock’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,231,552	Closed	-$28.4M	–	5431
2020 Q4	$28.4M	Sell	1,231,552 -773,808	-39%	-$9.81M	﹤0.01%	2821
2020 Q3	$20.4M	Buy	2,005,360 +559,017	+39%	+$7.5M	﹤0.01%	2848
2020 Q2	$21.6M	Buy	1,446,343 +312,364	+28%	+$4.81M	﹤0.01%	2753
2020 Q1	$13.8M	Buy	1,133,979 +422,205	+59%	+$6.72M	﹤0.01%	2809
2019 Q4	$11.3M	Buy	711,774 +267,040	+60%	+$3.41M	﹤0.01%	3189
2019 Q3	$5.46M	Buy	444,734 +344,734	+345%	+$3.91M	﹤0.01%	3462
2019 Q2	$1.32M	Buy	+100,000	New	+$1.46M	﹤0.01%	3924

BlackRock's PRVL Position: Q1 2021 in Review

BlackRock sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,231,552 shares — an estimated $28.4M sold.

BlackRock first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $28.4M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

BlackRock reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
BlackRock sold 1,231,552 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $28.4M.
BlackRock first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
BlackRock's Prevail Therapeutics Inc. Common Stock position peaked at $28.4M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on BlackRock's 13F filing for Q1 2021, filed 7 May 2021.